{
    "eid": "2-s2.0-85056445467",
    "title": "Neovascular age-related macular degeneration: Intraocular inflammatory cytokines in the poor responder to ranibizumab treatment",
    "cover-date": "2018-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Ophthalmology",
            "@code": "2731",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Anti-VEGF non-responder",
        "Choroidal neovascularization",
        "Neovascular age-related macular degeneration",
        "Poor responder",
        "Ranibizumab and AMD"
    ],
    "authors": [
        "Pear Pongsachareonnont",
        "Michael Ying Kit Mak",
        "Cameron Paul Hurst",
        "Wai Ching Lam"
    ],
    "citedby-count": 19,
    "ref-count": 59,
    "ref-list": [
        "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis",
        "Global estimates of visual impairment: 2010",
        "Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)",
        "Ranibizumab for neovascular age-related macular degeneration",
        "Ranibizumab versus verteporfin for neovascular age-related macular degeneration",
        "Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab",
        "Neovascular age-related macular degeneration: Intraocular cytokines and growth factors and the influence of therapy with ranibizumab",
        "Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration",
        "Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization",
        "VEGF-Trap: A VEGF blocker with potent antitumor effects",
        "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration",
        "Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies",
        "Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab",
        "Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration",
        "Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab",
        "Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)",
        "Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of a single treatment in a Phase 1 and 2 study",
        "Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization \u2013 verteporfin in photodynamic therapy report 2",
        "Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration",
        "Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: The TORPEDO trial at 2 years",
        "PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration",
        "Rescue Therapy With Combined Antivegf And Pdt For Refractory AMD",
        "Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab",
        "Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization",
        "Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration",
        "Fitting concentration and load rating curves with generalized linear models",
        "Monte Carlo Methods",
        "Propensity score estimation with boosted regression for evaluating causal effects in observational studies",
        "Gene selection and classification of microarray data using random forest",
        "Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization",
        "Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration",
        "Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen",
        "Reproducibility of refraction and visual acuity measurement under a standard protocol. The Macular Photocoagulation Study Group",
        "Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration",
        "Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: Time course and drug effects",
        "Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice",
        "IL-7 is critical for homeostatic proliferation and survival of naive T cells",
        "IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells",
        "IL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitis",
        "Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization",
        "ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7",
        "Intraocular and systemic inflam-mation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration",
        "Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments",
        "Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes",
        "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2",
        "Potential role of leptin in angiogenesis: Leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro",
        "Leptin, the product of Ob gene, promotes angiogenesis",
        "The role of leptin in choroidal neovascularization",
        "The many faces of interleukin-6: The role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis",
        "Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with and after bevacizumab treatment",
        "Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization",
        "Combination intravitreal ranibizumab 0.5 mg and verteporfin PDT versus verteporfin PDT alone in the FOCUS study of neovascular age-related macular degeneration (AMD)",
        "Combination Lucentis and Ocular Photodynamic Therapy with Visudyne, with Evaluation-Based Retreat-ments (CLOVER) Trial",
        "Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity",
        "Hepatocyte growth factor and its role in the pathogenesis of retinal detachment",
        "Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET",
        "Hepatocyte growth factor/ scatter factor in the eye"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60016849",
            "affilname": "University of Toronto",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016849",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60006541",
            "affilname": "The University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006541",
            "affiliation-country": "Hong Kong"
        }
    ],
    "funding": [
        "Association for Research in Vision and Ophthalmology",
        "Bayer Pharmaceuticals Inc."
    ]
}